Recent Updates
Recently added Catalysts
COLL

Collegium to Present at the Jefferies 2015 Global Healthcare Conference

Wednesday, May 27, 2015 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CANTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company's Chairman and CEO, Michael Heffernan, will present at the Jefferies 2015 Healthcare Conference in New York City. The presentation is scheduled for Monday

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
0.4%
average across 3 past catalysts
Lead asset
DFN-15 Active
Phase 3 · Migraine Headache

Full Press Release Details

CANTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company's Chairman and CEO, Michael Heffernan, will present at the Jefferies 2015 Healthcare Conference in New York City. The presentation is scheduled for Monday, June 1, 2015 at 1:30pm Eastern Time.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
ShareAdd on Google
Tags: COLL Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 27, 2015

Biotech snapshot

Cash runway
$150M liquidity · $0M/mo burn
Low dilution risk
Lead asset
DFN-15 ActivePhase 3
Migraine Headache →

Catalyst track record

+28%
best trade around COLL's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for COLL.

See every catalyst's timing & PoA →